NCT06805305 2026-04-14
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Diakonos Oncology Corporation
Phase 2 Recruiting
Clinical Trials
404 trialsNCT07326566 2026-04-14
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
Phase 2 Recruiting
NCT00268385 2026-04-13
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02152982 2026-04-13
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT03581292 2026-04-13
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05432804 2026-04-13
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
National Cancer Institute (NCI)
Phase 1/2 Suspended
NCT06419946 2026-04-13
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Vastra Gotaland Region
Phase 3 Recruiting
NCT03970447 2026-04-08
GBM AGILE
Global Coalition for Adaptive Research
Phase 2/3 Recruiting
NCT05095376 2026-04-03
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NRG Oncology
Phase 3 Active not recruiting
NCT06388733 2026-04-01
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
NeuroTrials, LLC
Phase 3 Recruiting
NCT02455557 2026-03-30
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Roswell Park Cancer Institute
Phase 2 Active not recruiting
NCT05765812 2026-03-30
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debiopharm International SA
Phase 1/2 Recruiting
NCT06934889 2026-03-30
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT03197506 2026-03-25
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
Mayo Clinic
Phase 2 Active not recruiting
NCT04574856 2026-03-25
Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT05843253 2026-03-20
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
NCT03491683 2026-03-19
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Inovio Pharmaceuticals
Phase 1/2 Active not recruiting
NCT05109728 2026-03-16
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Novartis
Phase 1 Active not recruiting
NCT03749187 2026-03-13
PNOC017
University of California, San Francisco
Phase 1 Active not recruiting
NCT06556563 2026-03-13
EF-41
NovoCure Ltd.
Phase 3 Recruiting
NCT02287428 2026-03-12
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT07297212 2026-03-12
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
Phase 2 Recruiting
NCT07452458 2026-03-05
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
NRG Oncology
Phase 3 Not yet recruiting
NCT05463848 2026-03-04
Surgical Pembro +/- Olaparib w TMZ for rGBM
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07195591 2026-03-04
BRIDGES
GT Medical Technologies, Inc.
Phase 3 Recruiting
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT02942264 2026-02-23
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT03514069 2026-02-19
Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT06448286 2026-02-19
PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma
Jonsson Comprehensive Cancer Center
Phase 3 Not yet recruiting
NCT03529448 2026-02-12
GEINOCANN
Grupo Español de Investigación en Neurooncología
Phase 1/2 Completed
NCT04478279 2026-02-09
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
Phase 1/2 Active not recruiting
NCT03405792 2026-02-06
2-THE-TOP
University of Florida
Phase 2 Active not recruiting
NCT07389278 2026-02-05
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
University of California, San Francisco
Phase 1/2 Not yet recruiting
NCT07391215 2026-02-05
5G-PEARL
Institute of Cancer Research, United Kingdom
Phase 1/2 Recruiting
NCT05739942 2026-02-03
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
Novartis
Phase 1 Active not recruiting
NCT05781321 2026-02-03
Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study
Mayo Clinic
Phase 2 Active not recruiting
NCT05629702 2026-01-30
ARISTOCRAT
University of Birmingham
Phase 2 Recruiting
NCT04752813 2026-01-26
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
BPGbio
Phase 2 Active not recruiting
NCT07365280 2026-01-26
Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma
ZSky Biotech Inc
Phase 2 Not yet recruiting
NCT04216329 2026-01-23
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT06630260 2026-01-21
5G-RUBY
Institute of Cancer Research, United Kingdom
Phase 1/2 Recruiting
NCT06105619 2026-01-20
A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
Beijing Pearl Biotechnology Limited Liability Company
Phase 2/3 Active not recruiting
NCT07349693 2026-01-20
Cerebraca-02/3
Everfront Biotech Co., Ltd.
Phase 2/3 Not yet recruiting
NCT02179086 2026-01-14
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
NRG Oncology
Phase 2 Active not recruiting
NCT04623931 2026-01-14
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05236036 2026-01-14
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
Northwestern University
Phase 1 Active not recruiting
NCT05083754 2026-01-09
Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Recruiting
NCT05106296 2026-01-09
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Augusta University
Phase 1 Recruiting
NCT06095375 2026-01-09
REGOMA-2
Istituto Oncologico Veneto IRCCS
Phase 1 Completed
NCT04049669 2026-01-08
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Augusta University
Phase 2 Active not recruiting